2,313 search results for “anti-cancer drug steen” in the Public website
-
Determining the kinetic profile of ENT1 inhibitors
Supervisor: Anna Vlachodimou
-
New platform to accelerate cardiac drug development
Researchers from Leiden University Medical Center (LUMC) and the Leiden-based biotech company Ncardia have joined forces to develop a new platform that enables the automated production of 3D cardiac microtissues. This platform will allow large numbers of drugs to be tested quickly
-
NMR Facility
Nuclear Magnetic Resonance (NMR) Spectroscopy is a non-destructive analytical technique that is used to study the nature and characteristics of molecules with an atomic level precision. It has a wide range of applications especially in synthetic chemistry, biological and biochemical research groups…
-
Cells with stress: predicting drug-induced liver and kidney damage
How can we prevent drug-induced liver and kidney damage? PhD candidates Marije Niemeijer and Lukas Wijaya investigated what happens in the cells during the onset of this damage: a stress response. Both focused on a different subtopic and made some interesting discoveries.
-
Promising new technique to treat cancer receives NWO grant
Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…
-
Bioprinting human tissues for drug testing
Bioprinters that enable scientists to engineer complex tissues and organs. It sounds like science-fiction, but not for the scientists of the Alireza Mashaghi lab at the Leiden Academic Centre for Drug Research. The lab has recently been equipped with two state-of-the-art bioprinters: BioX and LumenX+.…
-
Research
Research at the MCBIM group is comprised of the following research themes:
-
From scientific idea to promising new drug
Many pharmaceutical companies no longer have their own lab and are working more closely with universities and start-ups of scientists. Professor of Science-Based Business Simcha Jong is researching how scientific ideas result in new drugs, including at the Leiden Bio Science Park (LBSP).
-
Bioorthogonal Antigens as Tool for Investigation of Antigen Processing and Presentation
In order to be able to develop effective medicine and treatments to prevent or cure autoimmune diseases or cancer we need to understand the mechanisms how they arise and what drives their course.Unravelling the fundamental molecular mechanisms influencing the onset and course of diseases such as allergies,…
-
Advancing the LeiCNS-PK3.0 model for prediction of CNS Pharmacokinetics Nonlinear BBB Transport, Inter-species Scaling, and Machine Learning
This thesis focuses on enhancing predictions of central nervous system drug exposure using the LeiCNS-PK3.0, a physiologically based pharmacokinetic model.
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
Light and nanoparticles against cancer
Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…
-
Leiden-developed drug candidate ready for final clinical trial phase
Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.
-
Optimisation of first clinical studies in special populations: towards semi-physiological pharmacokinetic models
Promotor: M. Danhof, Co-promotores: J. Freijer, A. Yassen
-
De Witte et al publish in Nature Drug Discovery Reviews
Nature Reviews Drug Discovery volume 18, pages 82–84 (2019). The implications of target saturation for the use of drug–target residence time Wilbert de Witte, Meindert Danhof, Piet van der Graaf, and Elizabeth de Lange
-
Laura Heitman uses her expertise to fight cancer
Seven talented female scientists join the fight against cancer of the Oncode Insitute. Laura Heitman of the Leiden Academic Centre for Drug Research is one of the new Junior Investigators. ‘I hope to discover new druggable targets’.
-
Drug discovery 3.0: more effective and humane
Discovering effective new drugs is a long, expensive and uncertain process. Laura Heitman wants to improve this by finding out more about how drugs bind to proteins that play a role in disease. She calls it ‘drug discovery 3.0’. Inaugural lecture on 9 December.
-
Sensing drug responses of single cells using optical tweezers
Light can be used to apply forces on single cells. Focused lasers have been used by physicists to tweeze particles and to manipulate them. These so called “optical tweezers” can be used as mechanical phenotyping tools for characterising the mechanics of materials and living objects.
-
Impurities in sugar excipients could cause drugs to fail
Sugar excipients, needed to stabilize medicines, can be unsafe for patients due to an impurity discovered recently by Daniel Weinbuch. ‘The biopharmaceutical industry should now consider new excipient quality criteria for safer drug development,’ he says. PhD defence on 13 December.
-
GTGC lunch seminar: Santino Regilme on Global Drug Wars
On the 6th of March 2023, Santino Regilme presented his work-in-progress titled 'Global Drug Wars: Contested Normative Orders of Peace, Security, and Human Rights'. If the battle against illegal drugs is construed as a war, how is victory in such a war defined and constructed? If the oppositional…
-
Gut-on-chip good predictor of drug side-effects
Research conducted at Leiden has established that guts-on-chips respond in the same way to aspirin as real human organs do. This is a sign that these model organs are good predictors of the effect of medical drugs on the human body. Publication in Nature Communications on 15 August.
-
Mathematical model predicts drug concentration in the brain
Do medicines arrive in the right amount at the right spot in our brain? By making a model that depicts our brain in small 'brain blocks', Esmée Vendel tries to find an answer to this question. Her new, mathematical model predicts the concentration of medicines in the brain over time and space. Vendel…
-
Disrupting the transcriptional machinery to combat triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by limited treatment options and unfavorable clinical outcomes. Therefore, the research described in this thesis focused on the exploration of novel targeted therapies for TNBC.
-
Drug development: how can we make it more efficient?
It takes years to develop new medicines, from the test tube to trials in humans. During the process it often happens that a drug that seems promising in the initial stage has to be dropped in a later phase. This costs time and money. Leiden University and the LUMC are working closely together to make…
-
New potential cancer drugs and where to find them
Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…
-
Microneedle-mediated vaccine delivery
Promotores: Prof.dr. J. A. Bouwstra, Prof.dr. W. Jiskoot
-
Mexican drugs world pans out into hybrid war
Drugs-related violence in Mexico is similar in terms of dynamics and strategy to the IS hybrid war in the West. This is the claim made by Teun Voeten. PhD defence 20 September.
-
How Leiden's drug pioneers have switched to Covid research
From studying molecules in the blood of corona patients to developing a new concept for vaccines. The Leiden Academic Centre for Drug Research (LACDR) has transformed many ongoing projects into Covid research projects. Hubertus Irth, scientific director of LACDR, talks about the role of his institute…
-
Erik Danen appointed as Professor of Cancer drug target discovery
As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.
-
Countering nerve pain caused by chemotherapy with new drug
Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…
-
New project uses artificial intelligence in drug development
In health care, artificial intelligence is quite normal: it is used, for example, as an aid in making diagnoses. However, artificial intelligence is not yet used as much in drug development. A new prestigious partnership is therefore going to investigate how artificial intelligence can contribute to…
-
Monitoring Cytoskeletal Conductance Variation for Sensing Cancer Drug Resistance
Actin and microtubules form cellular cytoskeletal network, which mediates cell shape, motility and proliferation and are key targets for cancer therapy. Changes in cytoskeletal organization correlate with proliferative capacity and invasiveness of cancer cells. These changes expectedly lead to altered…
-
Hit and Lead Optimization
The goal of hit and lead optimization is to optimize suitable chemical starting points that can modulate a drug target. The methods and technologies used are similar to those in Hit Discovery, but once the compound has shown activity in an animal model, it moves from 'hit' to 'lead.'
-
Ovalbumin coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice
The aim of this work was to study the applicability of antigen-coated pH-sensitive microneedle arrays for effective vaccination strategies. Therefore, a model antigen (ovalbumin) was coated onto pH-sensitive (pyridine-modified) microneedle arrays to test pH-triggered antigen release by applying the…
-
Engineering of antigen-saving dissolving microneedles for intradermal vaccine delivery
The intradermal administration route is attractive for vaccine delivery, because of the highly populated antigen-presenting cells in the skin. However, the skin’s main physical barrier, the stratum corneum, prevents vaccines from entering the skin.
-
Bob van de Water -
How drugs work better when encapsulated in nanoparticles
Chemist Tobias Bauer discovered ways to improve drugs by encapsulating them. Packages with iron nanoparticles, for example, can stimulate immune cells. Bauer will receive his PhD on 9 June.
-
LACDR launches training programme for innovative drug development
The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.
-
Microphysiological liver systems for in vitro modeling and industry implementation
This thesis tackles the difficulty of predicting the liver’s clinical response to novel therapies, a challenge arising from interspecies differences and limitations of existing in vitro models.
-
Specialised immune cells have potential for new cancer immunotherapies
Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…
-
Bio-organic Synthesis
The research in the Biosyn group is focused on the design, synthesis and function of the four major types of biomolecules: nucleic acids, carbohydrates, peptides and lipids and hybrid structures thereof. These biomolecules and their derivatives are used in drug discovery and chemical biology, to develop…
-
The body's own marijuana as inspiration for drug research
Endocannabinoids - the body's own marijuana - are promising departure points for drug research. Professor of Molecular Physiology Mario van der Stelt examines whether inhibiting their production can be a way to fight inflammatory brain disease and to combat obesity. Inaugural lecture 19 October.
-
Innovation centre for drug development on Bio Science Park
International pharmaceuticals company Grünenthal is to open an innovation hub on the Leiden Bio Science Park. The hub will make it easier for scientists and drug developers to work together.
-
High throughput microscopy of mechanism-based reporters in druginduced liver injury
Promotor: B. van de Water
-
The role of glomerular filtration and active tubular secretion in predicting renal clearance in children using population pharmacokinetic and
In this thesis population pharmacokinetic and physiologically-based pharmacokinetic (PBPK) approaches were applied to investigate the influence of glomerular filtration (GF) and active tubular secretion (ATS) on renal clearance in children.
-
Memory before Modernity. Practices of Memory in Early Modern Europe
This volume discusses practices of memory in early modern Europe.
-
Sensing Transport
Solute carrier (SLC) transporters are a large and diverse class of relatively understudied transmembrane proteins.
-
Uncovering vulnerabilities in triple-negative breast cancer
Triple-negative breast cancer (TNBC) constitutes a small subtype (~15%) of breast cancer, but causes the majority of breast cancer-related deaths.
-
NMR structural studies of protein-small molecule interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal
-
Clavis Aurea? Structure-enabled approaches of identifying and optimizing GPCR ligands
Promotores: A.P. IJzerman, H.W.T. van Vlijmen